首页> 美国卫生研究院文献>Ocular Oncology and Pathology >Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma
【2h】

Eye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma

机译:弥漫性浸润性结膜黑色素瘤的抢眼治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.
机译:弥漫性浸润性结膜黑色素瘤患者的治疗重点在于局部肿瘤控制和转移筛查。尽管在前哨淋巴结活检对这些肿瘤的益处方面尚无共识,但通过组织病理学获得的信息可用于肿瘤分期和治疗计划。由于缺乏生存改善的证据,正在以越来越少的频率进行眼眶引出。我们描述了一名患有弥漫性浸润性结膜黑素瘤和淋巴结受累的患者,通过肿瘤减灭,近距离放疗(定制的非屏蔽放射性装置)和辅助ipilimumab治疗,在随访的16个月中,其结局良好,且未出现局部肿瘤复发或远处转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号